Daurismo (glasdegib) vs Brukinsa (zanubrutinib)
Daurismo (glasdegib) vs Brukinsa (zanubrutinib)
Daurismo (glasdegib) is a hedgehog pathway inhibitor used in combination with low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive induction chemotherapy. Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy, as well as for the treatment of Waldenström's macroglobulinemia and relapsed or refractory marginal zone lymphoma. When deciding between these two medications, it is crucial to consider the specific type of blood cancer being treated, as Daurismo is tailored for certain AML patients, while Brukinsa is designed for different forms of B-cell malignancies, and the decision should be made in close consultation with a healthcare provider specializing in oncology.
Difference between Daurismo and Brukinsa
| Metric | Daurismo (glasdegib) | Brukinsa (zanubrutinib) |
|---|---|---|
| Generic name | Glasdegib | Zanubrutinib |
| Indications | Acute myeloid leukemia (AML) | Mantle cell lymphoma (MCL), Waldenström's macroglobulinemia |
| Mechanism of action | Hedgehog pathway inhibitor | Bruton's tyrosine kinase (BTK) inhibitor |
| Brand names | Daurismo | Brukinsa |
| Administrative route | Oral | Oral |
| Side effects | Anemia, fatigue, hemorrhage, febrile neutropenia, muscle pain | Neutropenia, thrombocytopenia, anemia, diarrhea, bruising |
| Contraindications | Hypersensitivity to glasdegib or any component of the formulation | Hypersensitivity to zanubrutinib or any component of the formulation |
| Drug class | Antineoplastic agent | Antineoplastic agent |
| Manufacturer | Pfizer | BeiGene |
Efficacy
Efficacy of Daurismo (glasdegib) in Leukemia
Daurismo (glasdegib) has been shown to be effective in the treatment of acute myeloid leukemia (AML), particularly in a specific subset of patients. Clinical trials have demonstrated that when glasdegib is combined with low-dose cytarabine (LDAC), a chemotherapy drug, it can significantly improve the overall survival rates in adult patients with newly-diagnosed AML who are over 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. The efficacy of Daurismo in this context is particularly important as it provides a treatment option for patients who are unable to tolerate more aggressive AML therapies.
In a pivotal phase 2 study known as BRIGHT 1003, patients treated with the combination of Daurismo and LDAC had a median overall survival of 8.3 months compared to 4.3 months for those who received LDAC alone. This improvement in survival is significant, indicating that Daurismo can play a crucial role in the management of AML in a population of patients with limited treatment options.
Efficacy of Brukinsa (zanubrutinib) in Leukemia
Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that has been studied for its efficacy in treating various types of leukemia, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), which is a subtype of non-Hodgkin's lymphoma rather than leukemia. However, it's important to note that its primary indications and clinical trial results have been focused on these lymphomas rather than leukemia per se.
While there is ongoing research regarding the efficacy of zanubrutinib in other leukemic conditions, the most robust data currently available pertains to its use in CLL and MCL. In clinical trials, zanubrutinib has shown high response rates and durable responses in patients with these conditions. For instance, in the phase 3 SEQUOIA trial, zanubrutinib demonstrated a high overall response rate in patients with treatment-naïve CLL. Additionally, in the phase 2 BGB-3111-206 trial for patients with relapsed/refractory MCL, zanubrutinib achieved a high overall response rate, indicating its potential as an effective treatment option in these patient populations.
Regulatory Agency Approvals
Daurismo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
Brukinsa
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Daurismo or Brukinsa today
If Daurismo or Brukinsa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us